Jurecka, Agnieszka Tylki-Szymanska, Anna
Published in
Molecular genetics and metabolism
Inborn errors of purine and pyrimidine (P/P) metabolism are under-reported and rarely mentioned in the general literature or in clinical practice, as well as in reviews dedicated to other inborn errors of metabolism (IEMs). However, their diagnosis is important because genetic counseling can be provided and, in some cases, specific treatment exists...
Jin, Xin; Zhao, Li-Min; Wang, Shuai; Huang, Wen-Juan; Zhang, Yin-Xiang; Pannecouque, Christophe; 16599; De Clercq, Erik; 3934; Chen, Fen-Er;
Results from recently completed studies suggested that the NH2-naphthyl-diarylpyrimidine JX-7 displayed remarkable inhibitory activity against wild-type HIV-1 (EC50 = 5 nM) and numerous clinically observed variants in MT-4 cells; however, its high cytotoxicity (CC50 = 19 μM) precluded its further development as a clinical candidate. One approach we...
Wu, Zhi-Chen Houk, KN Boger, Dale L Svatunek, Dennis
1,2,3-Triazines and 1,2,3,5-tetrazines react rapidly, efficiently, and selectively with amidines to form pyrimidines/1,3,5-triazines, exhibiting an orthogonal reactivity with 1,2,4,5-tetrazine-based conjugation chemistry. Whereas the mechanism of the reaction of the isomeric 1,2,4-triazines and 1,2,4,5-tetrazines with alkenes is well understood, th...
Barr, Paul M Owen, Carolyn Robak, Tadeusz Tedeschi, Alessandra Bairey, Osnat Burger, Jan A Hillmen, Peter Coutre, Steven E Dearden, Claire Grosicki, Sebastian
...
We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients (≥65 years) with previously ...
Taghavi, Amirhossein Riveros, Ivan Wales, David J Yildirim, Ilyas
RNA modulation via small molecules is a novel approach in pharmacotherapies, where the determination of the structural properties of RNA motifs is considered a promising way to develop drugs capable of targeting RNA structures to control diseases. However, due to the complexity and dynamic nature of RNA molecules, the determination of RNA structure...
Kuter, David Rogers, Kerry Boxer, Michael Choi, Michael Agajanian, Richy Arnold, Donald Broome, Catherine Field, Joshua Murakhovskaya, Irina Numerof, Robert
...
Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). This phase 2 study evaluated the response to fostamat...
Chiriapkin, Alexey Kodonidi, Ivan Pozdnyakov, Dmitry
Published in
Iranian Journal of Pharmaceutical Research : IJPR
Background The high prevalence of skin hyperpigmentation makes it necessary to search for remedies that could hinder this process. Among such substances, tyrosinase inhibitors can be distinguished, which may be pyrimidine derivatives. Objectives This study aimed to investigate new compounds with anti-tyrosinase activity in 2-substituted tetrahydrob...
Peiris, Malalage N Meyer, April N Warda, Dalida Campos, Alexandre Rosa Donoghue, Daniel J
Translocation of Fibroblast Growth Factor Receptors (FGFRs) often leads to aberrant cell proliferation and cancer. The BCR-FGFR1 fusion protein, created by chromosomal translocation t(8;22)(p11;q11), contains Breakpoint Cluster Region (BCR) joined to Fibroblast Growth Factor Receptor 1 (FGFR1). BCR-FGFR1 represents a significant driver of 8p11 myel...
Ferng, Timothy T Terada, Daisuke Ando, Makoto Tarver, Theodore C Chaudhary, Fihr Lin, Kimberly C Logan, Aaron C Smith, Catherine C
Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance remains an important clinical problem. FF-10101 is the first irreversible, covalent inhibitor of FLT3 which has previously shown activity against FLT3 tyrosine kinase inhi...
Wu, Qibiao Zhen, Yuanli Shi, Lei Vu, Phuong Greninger, Patricia Adil, Ramzi Merritt, Joshua Egan, Regina Wu, Meng-Ju Yin, Xunqin
...
FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined mechanisms. Here, we conducted high-throughput combination drug screens, biochemical analysis, and therap...